EXEL Stock Risk & Deep Value Analysis
Exelixis Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About EXEL Stock
We analyzed Exelixis Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran EXEL through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate-High. Here's what we found.
EXEL Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk for Exelixis is the potential for zanzalintinib (XL092) to not receive FDA approval for metastatic colorectal cancer by its PDUFA date of December 3, 2026. This would significantly reduce the company's immediate future growth prospects beyond Cabometyx and could cause a substantial stock price correction, impacting future R&D investment and investor confidence in its pipeline strategy.
Risk Matrix
Overall
Moderate-High
Financial
Low
Market
Medium
Competitive
High
Execution
Medium
Regulatory
High
Red Flags
- ⚠
High reliance on Cabometyx for primary revenue, representing approximately 90% of net product revenue (based on Q1 2026 data).
- ⚠
Pipeline failures or delays for other assets beyond zanzalintinib, limiting long-term growth diversification.
- ⚠
Intense competitive landscape in oncology with larger pharmaceutical companies, requiring substantial R&D investment to maintain market position.
Upcoming Risk Events
- 📅
Zanzalintinib FDA rejection or significant delay (2026-12-03): Failure to approve could lead to a 20-30% stock price decline and delay significant revenue diversification.
- 📅
Increased competitive pressure or patent expiry for Cabometyx (ongoing): Could lead to decelerated growth or revenue decline for the primary revenue driver, impacting overall profitability and future R&D funding.
When to Reconsider
- 🚪
Exit if quarterly Cabometyx net product revenue growth falls below 5% YoY for two consecutive quarters.
- 🚪
Sell if zanzalintinib NDA is rejected or significantly delayed beyond mid-2027.
- 🚪
Exit if cash and marketable securities fall below $800M without clear justification for increased R&D spend or M&A.
Unlock EXEL Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Exelixis Inc (EXEL) Do?
Market Cap
$12.55B
Sector
Healthcare
Industry
Biotechnology
Employees
1,147
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an ADC consisting of a MMAE payload conjugated to a human mAb targeting the tumor antigen 5T4; and XL495, a small molecule inhibitor of PKMYT1. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent Pharma Solutions, Inc.; Iconic Therapeutics, Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Visit Exelixis Inc WebsiteInvestment Thesis
If zanzalintinib (XL092) secures FDA approval for metastatic colorectal cancer by Q4 2026 and achieves initial peak sales forecasts of $1.5B-$2B in mCRC and other indications, combined with continued robust Cabometyx growth and further advancements in its deep oncology pipeline, Exelixis could significantly expand its market leadership in targeted cancer therapies. This is bullish because the market may currently undervalue the multi-indication, multi-billion dollar potential of zanzalintinib as it progresses through regulatory and clinical milestones.
Is EXEL Stock Undervalued?
Unlock the full AI analysis for EXEL
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
EXEL Price Targets & Strategy
12-Month Target
$72.00
Bull Case
$85.00
Bear Case
$45.00
Valuation Basis
Based on 22x forward P/E applied to an estimated FY2026 EPS of $3.27 (extrapolated from Q1 beat and growth), providing a $71.94 target.
Entry Strategy
Consider dollar-cost averaging between $47-$50, targeting dips towards recent support levels or the 50-day moving average (if aligned).
Exit Strategy
Take partial profits at $70-$75, with a stop-loss order set at $45 to protect against downside risk, especially if zanzalintinib approval faces setbacks.
Portfolio Allocation
5% for moderate risk tolerance
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is EXEL Financially Healthy?
Valuation
P/E Ratio
15.06
Forward P/E
14.70
EV/EBITDA
12.90
PEG Ratio
1.80
Price/Book
4.70
Price/Sales
5.90
Profitability
Gross Margin
96.44%
Operating Margin
39.43%
Net Margin
35.08%
Return on Equity
40.21%
Revenue Growth
7.91%
EPS
$3.02
Balance Sheet
Current Ratio
3.56
Quick Ratio
3.32
Cash & Equivalents
$1.57B
Cash Flow
Operating Cash Flow
$820.00M
Free Cash Flow
$760.00M
EBITDA
$965.00M
Other
Beta (Volatility)
0.41
Does EXEL Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
2 Identified
The moat primarily derives from its intellectual property on approved and pipeline drugs. This provides durable protection but is finite due to patent expiry. Successful development and commercialization of new drugs continuously renew and extend this moat.
Moat Erosion Risks
- •Patent expiry for Cabometyx, leading to generic competition and revenue erosion (anticipated in the 2030s).
- •Development of superior or more cost-effective competitor drugs in its core indications.
- •Clinical trial failures for key pipeline candidates, limiting future revenue diversification.
EXEL Competitive Moat Analysis
Sign up to see competitive advantages
EXEL Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bullish, driven by positive earnings and pipeline updates, but tempered by high valuation multiples for future growth.
Institutional Sentiment
Positive, indicated by EPS beat and ongoing analyst coverage, though specific upgrade/downgrade data is not provided in research.
Insider Activity (Form 4)
Christopher J. Senner, EVP & CFO, filed a Form 4 on 2026-05-15, but the specifics of shares bought/sold and dollar value were not disclosed in the provided source.
Options Flow
Normal options activity (no specific unusual activity identified in the provided research).
Earnings Intelligence
Next Earnings
Estimated late July/early August 2026 (for Q2 2026)
Surprise Probability
Medium-High (based on Q1 2026 EPS beat)
Historical Earnings Pattern
Historically, Exelixis tends to react positively to earnings beats and pipeline progress, with potential volatility around regulatory decisions for key drugs.
Key Metrics to Watch
Competitive Position
Top Competitor
Not explicitly detailed in provided research, but key competitors include other oncology biopharma companies with targeted therapies (e.g., Pfizer, Bristol Myers Squibb, Novartis in specific indications).
Market Share Trend
Stable to Gaining (Cabometyx maintains strong market share in its approved indications, while zanzalintinib aims to gain new share in mCRC).
Valuation vs Peers
Valuation data (P/E, EV/EBITDA) not provided for direct comparison. However, given its profitability and growth, it likely trades at a premium to broader pharmaceutical averages but potentially in line with or slightly above high-growth oncology peers.
Competitive Advantages
- •Strong intellectual property and patent protection for Cabometyx and pipeline assets like zanzalintinib.
- •Deep expertise and established presence in the competitive oncology therapeutic area.
- •Robust cash position for R&D and potential M&A to expand pipeline.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive EXEL Stock Higher?
Near-Term (0-6 months)
- •Zanzalintinib FDA PDUFA date for mCRC (2026-12-03): Potential approval for new drug, generating initial sales and re-rating of pipeline value.
- •Q2 2026 Earnings Report (estimated late July/early August 2026): Continued strong Cabometyx revenue growth and positive updates on zanzalintinib launch preparations and other pipeline assets.
Medium-Term (6-18 months)
- •Zanzalintinib commercial launch and initial market penetration (H1 2027): If uptake is strong, could add an estimated $100M-$200M in incremental revenue in its first full year.
- •Additional zanzalintinib clinical trial readouts for other indications (FY2027): Positive data could expand the drug's total addressable market and revenue potential beyond mCRC.
Long-Term (18+ months)
- •Multiple new blockbuster drug approvals and launches (FY2028-FY2030): Success with 2-3 additional multi-billion dollar drugs could drive market cap towards $50B+.
- •Strategic expansion into new oncology therapeutic areas (FY2029-FY2031): Diversification beyond current focus, leveraging R&D expertise to capture additional market share in high-growth segments, potentially adding $1B+ in new revenue streams.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for EXEL?
- ✓
Watch zanzalintinib's first full year of sales post-approval — crossing $150M in revenue signals strong market adoption.
- ✓
Monitor Cabometyx net product revenue growth — sustained growth above 7% YoY indicates continued market strength and pricing power.
Bull Case Analysis
Sign up free to see the bull case
Competing with EXEL
See how Exelixis Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Exelixis Inc EXEL | $12.6B | 0.9 | 15.1 | $2.3B | 35.1% | 7.9% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Exelixis Inc Makes Money
Exelixis is a biopharmaceutical company focused on discovering, developing, and commercializing innovative small molecule therapeutics for challenging cancers. Its primary revenue stream comes from its flagship drug, Cabometyx (cabozantinib), which is approved for various forms of kidney, liver, and thyroid cancer. The company invests heavily in research and development to expand the indications for its existing drugs and bring new compounds, like zanzalintinib, through clinical trials and regulatory approval, aiming to create a diversified portfolio of oncology treatments.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Exelixis Inc (EXEL)?
As of May 22, 2026, Exelixis Inc has a DVR Score of 0.9 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Exelixis Inc?
Exelixis Inc's market capitalization is approximately $12.6B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Exelixis Inc use?
EXEL is the ticker symbol for Exelixis Inc. The company trades on the NMS.
What is the risk level for EXEL stock?
Our analysis rates Exelixis Inc's overall risk as Moderate-High. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of EXEL?
Exelixis Inc currently has a price-to-earnings (P/E) ratio of 15.1. This is in line with broader market averages.
Is Exelixis Inc's revenue growing?
Exelixis Inc has reported revenue growth of 7.9%. The company is growing at a moderate pace.
Is EXEL stock profitable?
Exelixis Inc has a profit margin of 35.1%. This indicates strong profitability.
How often is the EXEL DVR analysis updated?
Our AI-powered analysis of Exelixis Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 22, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for EXEL (Exelixis Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.